Program Overview
Pulmonary arterial hypertension (PAH) is a severe disease causing increased pulmonary vascular resistance eventually leading to right heart failure and death. Development of PAH is multifactorial but is frequently associated with connective tissue diseases (CTD-PAH). CTD-PAH comprises nearly 30% of all PAH cases and includes connective tissue diseases such as systemic sclerosis, systemic lupus erythematosus, and mixed connective tissue disease. Progress has been made in further understanding the pathophysiology of CTD-PAH with development of effective treatments that have improved survival for this devastating illness. This activity will provide pharmacists with an in-depth review of CTD-PAH management and treatment guidelines including recent data to best manage patients’ treatment expectations.
Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: November 15, 2021
Expiration date: November 15, 2022
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, the participant will be able to:
- Examine the epidemiology, pathophysiology, risk factors, prognosis and challenges associated with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)
- Explore the mechanisms of action and efficacy and safety data associated with therapies for CTD-PAH
- Use current guidelines to tailor therapy to meet individual patient goals
- Identify the role of the pharmacist in making clinical recommendations to improve management and clinical outcomes in patients with CTD-PAH
Kristen T. Pogue, PharmD, BCCP
Clinical Pharmacy Specialist, Cardiology
Michigan Medicine
Clinical Associate Professor
University of Michigan College of Pharmacy
Residency Program Director
PGY2 Cardiology Pharmacy Residency
Michigan Medicine
Ann Arbor, Michigan
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-360-H01-P. The activity is available for CE credit through November 15, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Kristen T. Pogue, PharmD, BCCP, has the following financial relationships with commercial interests to disclose:
Consultant (Spouse): Merck & Co, Shionogi, Qpex, Entasis, Utility, Union, Ferring, Accelerate, BioFire, Roche
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times® Editorial Staff—Davy James
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Medical reviewer Stormi Gale, PharmD, BCCP, has the following financial relationship with a commercial interest to disclose:
Consultant: United Therapeutics Corporation
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here